{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:07:10Z","timestamp":1792069630328,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K08-DK124577"],"award-info":[{"award-number":["K08-DK124577"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jceh.2023.05.002","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T12:19:13Z","timestamp":1683893953000},"page":"1032-1046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Statins in Cirrhosis: Hope or Hype?"],"prefix":"10.1016","volume":"13","author":[{"given":"Lauren R.","family":"Shaffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1889-3954","authenticated-orcid":false,"given":"Nadim","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2023.05.002_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/hep.29277","article-title":"Statins in cirrhosis-Ready for prime time","volume":"66","author":"Tsochatzis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2023.05.002_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.112.145334","article-title":"Statins as antithrombotic drugs","volume":"127","author":"Violi","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jceh.2023.05.002_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cld.788","article-title":"Patients with chronic liver disease\/cirrhosis should not take statin medications","volume":"13","author":"Kasia","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2023.05.002_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1053\/j.gastro.2010.10.031","article-title":"Prolonging survival in patients with cirrhosis: old drugs with new indications","volume":"139","author":"Tsochatzis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2023.05.002_bib5","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","article-title":"Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia","volume":"61","author":"Blais","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2023.05.002_bib6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cld.2019.07.007","article-title":"Portal hypertension: pathogenesis and diagnosis","volume":"23","author":"Turco","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2023.05.002_bib7","doi-asserted-by":"crossref","first-page":"G407","DOI":"10.1152\/ajpgi.00441.2016","article-title":"Rationale for the use of statins in liver disease","volume":"312","author":"Schierwagen","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jceh.2023.05.002_bib8","doi-asserted-by":"crossref","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and Ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jceh.2023.05.002_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1172\/JCI24787","article-title":"Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2","volume":"116","author":"Parmar","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jceh.2023.05.002_bib10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","volume":"69","author":"Bosch","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2023.05.002_bib11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2023.05.002_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/gut.2010.220913","article-title":"Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver","volume":"60","author":"Gracia-Sancho","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2023.05.002_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins","volume":"58","author":"Marrone","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2023.05.002_bib15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12876-015-0248-8","article-title":"Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells","volume":"15","author":"Chong","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jceh.2023.05.002_bib17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1476-5381.2008.00043.x","article-title":"Simvastatin protects against cholestasis-induced liver injury","volume":"156","author":"Dold","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jceh.2023.05.002_bib18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","author":"Trebicka","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1478-3231.2011.02579.x","article-title":"Endothelial dysfunction in the regulation of cirrhosis and portal hypertension","volume":"32","author":"Iwakiri","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2023.05.002_bib20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/jhep.2002.31432","article-title":"The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough","volume":"35","author":"Wiest","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2023.05.002_bib21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4254\/wjh.v9.i5.270","article-title":"Addition of simvastatin to carvedilol non responders: a new pharmacological therapy for treatment of portal hypertension","volume":"9","author":"Wani","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib22","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats","volume":"46","author":"Abraldes","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1440-1746.2009.06159.x","article-title":"Simvastatin effects on portal-systemic collaterals of portal hypertensive rats","volume":"25","author":"Huang","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00007890-200102270-00008","article-title":"Endogenous nitric oxide and exogenous nitric oxide supplementation in hepatic ischemia-reperfusion injury in the rat","volume":"71","author":"Peralta","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2023.05.002_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/srep22107","article-title":"Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy","volume":"6","author":"Hide","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jceh.2023.05.002_bib26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/SHK.0000000000000734","article-title":"Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to hemorrhage\/resuscitation","volume":"47","author":"Meireles","year":"2017","journal-title":"Shock"},{"key":"10.1016\/j.jceh.2023.05.002_bib27","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2013.02.005","article-title":"Simvastatin maintains function and viability of steatotic rat livers procured for transplantation","volume":"58","author":"Gracia-Sancho","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib29","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jhep.2021.12.034","article-title":"Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort","volume":"76","author":"Mahmud","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib30","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis","volume":"156","author":"Kaplan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2023.05.002_bib31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2023.05.002_bib32","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.29172","article-title":"Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study","volume":"66","author":"Chang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2023.05.002_bib33","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","article-title":"Statin use in patients with cirrhosis: a retrospective cohort study","volume":"59","author":"Kumar","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2023.05.002_bib34","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.14243","article-title":"Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study","volume":"46","author":"Bang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2023.05.002_bib35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ajg.2016.179","article-title":"Statins reduce the risk of\u00a0cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study","volume":"111","author":"Huang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2023.05.002_bib36","doi-asserted-by":"crossref","first-page":"100740","DOI":"10.1016\/j.jhepr.2023.100740","article-title":"Association between statin\u00a0exposure and short-term mortality in patients with high-grade acute-on-chronic liver failure","volume":"5","author":"Chapin","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2023.05.002_bib37","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2023.05.002_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jceh.2023.05.002_bib40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.12688\/f1000research.13915.1","article-title":"Evaluation of portal pressure by Doppler ultrasound in patients with cirrhosis before and after simvastatin administration - a randomized controlled trial","volume":"7","author":"Elwan","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.jceh.2023.05.002_bib41","doi-asserted-by":"crossref","first-page":"729","DOI":"10.14309\/ajg.0000000000000551","article-title":"Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial","volume":"115","author":"Vijayaraghavan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2023.05.002_bib42","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2023.05.002_bib43","unstructured":"Rezende G. Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension (Betastatin). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03720067."},{"key":"10.1016\/j.jceh.2023.05.002_bib44","unstructured":"Sinn D. Atorvastatin Use and Portal Hypertension in Patients with\u00a0Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial (STAPH). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05483894."},{"key":"10.1016\/j.jceh.2023.05.002_bib45","unstructured":"Kaplan D. Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting with High-Risk Compensated Cirrhosis (SACRED). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03654053."},{"key":"10.1016\/j.jceh.2023.05.002_bib46","unstructured":"Kronborg T. Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis (STATLiver). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04072601."},{"key":"10.1016\/j.jceh.2023.05.002_bib47","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00134-014-3418-1","article-title":"Effect of the use of low and high potency statins and sepsis outcomes","volume":"40","author":"Ou","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jceh.2023.05.002_bib48","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/apt.12430","article-title":"Statin use and infections in Veterans with cirrhosis","volume":"38","author":"Motzkus-Feagans","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2023.05.002_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2010.02.013","article-title":"The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis","volume":"25","author":"Janda","year":"2010","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.jceh.2023.05.002_bib50","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.amjmed.2014.10.057","article-title":"Statin therapy and mortality from sepsis: a meta-analysis of randomized trials","volume":"128","author":"Deshpande","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jceh.2023.05.002_bib51","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1440-1746.2012.07232.x","article-title":"Potential for statins in the chemoprevention and management of hepatocellular carcinoma","volume":"27","author":"Lonardo","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317734947","article-title":"Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells","volume":"39","author":"Fujiwara","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jceh.2023.05.002_bib53","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3892\/ijo.2010.892","article-title":"Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK","volume":"38","author":"Relja","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jceh.2023.05.002_bib54","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/0008-5472.CAN-10-3367","article-title":"MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase","volume":"71","author":"Cao","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jceh.2023.05.002_bib55","first-page":"190","article-title":"Statins and hepatocellular carcinoma protection","volume":"15","author":"Kaplan","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2023.05.002_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.28506","article-title":"Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES","volume":"64","author":"Simon","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2023.05.002_bib58","unstructured":"Goodman M. Simvastatin in Preventing Liver Cancer in Patients with Liver Cirrhosis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02968810."},{"key":"10.1016\/j.jceh.2023.05.002_bib59","unstructured":"Chung R. Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk (TORCH). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05028829."},{"key":"10.1016\/j.jceh.2023.05.002_bib60","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jceh.2023.05.002_bib61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2023.05.002_bib62","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5114\/aoms.2015.50972","article-title":"Improvement of hepatic bioavailability as a new step for the future of statin","volume":"11","author":"Petyaev","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jceh.2023.05.002_bib63","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156720109789000519","article-title":"Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs","volume":"6","author":"Patel","year":"2009","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.jceh.2023.05.002_bib64","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.2042-7158.2011.01273.x","article-title":"Statins therapy: a review on conventional and novel formulation approaches","volume":"63","author":"Tiwari","year":"2011","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.jceh.2023.05.002_bib65","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12944-019-1139-8","article-title":"Parenteral systems for statin delivery: a review","volume":"18","author":"Korani","year":"2019","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jceh.2023.05.002_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/polym13050711","article-title":"Polymers and nanoparticles for statin delivery: current use and future perspectives in cardiovascular disease","volume":"13","author":"Nenna","year":"2021","journal-title":"Polymers"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688323000798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688323000798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:11:11Z","timestamp":1760854271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688323000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0973688323000798"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2023.05.002","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins in Cirrhosis: Hope or Hype?","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2023.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}